Combating the epigenome: epigenetic drugs against non-Hodgkin's lymphoma.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Epigenomics

• Publication date

  2013-07-29

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.2217/epi.13.39PMID 23895653
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Methods for cancer epigenome analysis.

  2013cited by this paper
• Pharmacokinetic and pharmacodynamic analysis of 5-aza-2’-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy

  2013cited by this paper
• Histone deacetylase (HDAC) 1 and 2 are essential for normal T cell development and genomic stability in mice

  2013cited by this paper
• Dnmt3b is a haploinsufficient tumor suppressor gene in Myc-induced lymphomagenesis.

  2013cited by this paper
• The histone deacetylase inhibitor valproic acid sensitizes diffuse large B-cell lymphoma cell lines to CHOP-induced cell death.

  2013cited by this paper
• Dosage-dependent tumor suppression by histone deacetylases 1 and 2 through regulation of c-Myc collaborating genes and p53 function.

  2013cited by this paper
• Nahuoic acid A produced by a Streptomyces sp. isolated from a marine sediment is a selective SAM-competitive inhibitor of the histone methyltransferase SETD8.

  2013cited by this paper
• A dual role for Hdac1: oncosuppressor in tumorigenesis, oncogene in tumor maintenance.

  2013cited by this paper
• Genetic and epigenetic basis of chronic lymphocytic leukemia

  2013cited by this paper
• EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations

  2012cited by this paper
• The genetic landscape of mutations in Burkitt lymphoma

  2012cited by this paper
• MYD88 L265P mutation in Waldenstrom macroglobulinemia.

  2012cited by this paper
• Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics

  2012cited by this paper
• TET2 and DNMT3A mutations in human T-cell lymphoma.

  2012cited by this paper
• Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27)

  2012cited by this paper
• Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-Cell lymphomas.

  2012cited by this paper
• In situ mantle cell lymphoma: clinical implications of an incidental finding with indolent clinical behavior

  2012cited by this paper
• Regulation of STAT3 by histone deacetylase-3 in diffuse large B-cell lymphoma: implications for therapy

  2012cited by this paper
• Role of histone deacetylase inhibitors in the treatment of lymphomas and multiple myeloma.

  2012cited by this paper
• Histone deacetylase inhibitor potentiates chemotherapy-induced apoptosis through Bim upregulation in Burkitt’s lymphoma cells

  2012cited by this paper
• Superior Efficacy of a Combined Epigenetic Therapy against Human Mantle Cell Lymphoma Cells

  2012cited by this paper
• The bromodomain interaction module

  2012cited by this paper
• Antineoplastic activity of the DNA methyltransferase inhibitor 5-aza-2′-deoxycytidine in anaplastic large cell lymphoma

  2012cited by this paper
• Haploinsufficiency of Dnmt1 impairs leukemia stem cell function through derepression of bivalent chromatin domains.

  2012cited by this paper
• A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells.

  2012cited by this paper
• Effects of tetrahydrouridine on pharmacokinetics and pharmacodynamics of oral decitabine.

  2012cited by this paper
• Myc represses miR-15a/miR-16-1 expression through recruitment of HDAC3 in mantle cell and other non-Hodgkin B-cell lymphomas

  2012cited by this paper
• Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma.

  2012cited by this paper
• Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing

  2012cited by this paper
• Sinefungin derivatives as inhibitors and structure probes of protein lysine methyltransferase SETD2.

  2012cited by this paper
• A687V EZH2 is a gain‐of‐function mutation found in lymphoma patients

  2012cited by this paper
• Combined effect of histone deacetylase inhibitor suberoylanilide hydroxamic acid and anti-CD20 monoclonal antibody rituximab on mantle cell lymphoma cells apoptosis.

  2012cited by this paper
• Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy.

  2012cited by this paper
• Hepatitis viruses and non-Hodgkin lymphoma: epidemiology, mechanisms of tumorigenesis, and therapeutic opportunities.

  2011cited by this paper
• Discovery and characterization of small molecule inhibitors of the BET family bromodomains.

  2011cited by this paper
• The biology of HDAC in cancer: the nuclear and epigenetic components.

  2011cited by this paper
• Frequent mutation of histone modifying genes in non-Hodgkin lymphoma

  2011cited by this paper
• Follicular lymphoma in situ: clinical implications and comparisons with partial involvement by follicular lymphoma.

  2011cited by this paper
• Analysis of the Coding Genome of Diffuse Large B-Cell Lymphoma

  2011cited by this paper
• Romidepsin: a novel histone deacetylase inhibitor for cancer

  2011cited by this paper
• Oncogenically active MYD88 mutations in human lymphoma

  2011cited by this paper
• Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma.

  2011cited by this paper
• Targeting MYC dependence in cancer by inhibiting BET bromodomains

  2011cited by this paper
• Dnmt3a is essential for hematopoietic stem cell differentiation

  2011cited by this paper
• BET bromodomain inhibition as a therapeutic strategy to target c-Myc.

  2011cited by this paper
• Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation.

  2011cited by this paper
• HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL.

  2011cited by this paper
• Phase I Study of Decitabine in Combination with Vorinostat in Patients with Advanced Solid Tumors and Non-Hodgkin's Lymphomas

  2011cited by this paper
• Overexpression of enhancer of zeste homolog 2 with trimethylation of lysine 27 on histone H3 in adult T-cell leukemia/lymphoma as a target for epigenetic therapy

  2011cited by this paper
• Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma.

  2011cited by this paper
• Selective inhibition of BET bromodomains

  2010cited by this paper
• Somatic mutation of EZH2 (Y641) in Follicular and Diffuse Large B-cell Lymphomas of Germinal Center Origin

  2010cited by this paper
• Suppression of inflammation by a synthetic histone mimic

  2010cited by this paper
• Inactivating mutations of acetyltransferase genes in B-cell lymphoma

  2010cited by this paper
• DNMT3B7, a truncated DNMT3B isoform expressed in human tumors, disrupts embryonic development and accelerates lymphomagenesis.

  2010cited by this paper
• Gene expression profiling identifies emerging oncogenic pathways operating in extranodal NK/T-cell lymphoma, nasal type.

  2010cited by this paper
• Deregulated expression of the polycomb-group protein SUZ12 target genes characterizes mantle cell lymphoma.

  2010cited by this paper
• DNA methyltransferase DNMT3b protein overexpression as a prognostic factor in patients with diffuse large B‐cell lymphomas

  2010cited by this paper
• Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma.

  2010cited by this paper
• Chemical Phylogenetics of Histone Deacetylases

  2010cited by this paper
• Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes

  2010cited by this paper
• Phase I trial of low dose decitabine targeting DNA hypermethylation in patients with chronic lymphocytic leukaemia and non‐Hodgkin lymphoma: dose‐limiting myelosuppression without evidence of DNA hypomethylation

  2010cited by this paper
• Characterization of an antagonistic switch between histone H3 lysine 27 methylation and acetylation in the transcriptional regulation of Polycomb group target genes

  2010cited by this paper
• EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis.

  2010cited by this paper
• Somatic mutations of the histone H3K27 demethylase, UTX, in human cancer

  2009cited by this paper
• Histone deacetylase 1, 2, 6 and acetylated histone H4 in B‐ and T‐cell lymphomas

  2009cited by this paper
• Expression of histone deacetylases in lymphoma: implication for the development of selective inhibitors

  2009cited by this paper
• New insights into the biology and origin of mature aggressive B-cell lymphomas by combined epigenomic, genomic, and transcriptional profiling.

  2009cited by this paper
• Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma.

  2009cited by this paper
• Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance.

  2009cited by this paper
• HDAC2 negatively regulates memory formation and synaptic plasticity

  2009cited by this paper
• Gene expression profiling of isolated tumour cells from anaplastic large cell lymphomas: insights into its cellular origin, pathogenesis and relation to Hodgkin lymphoma

  2009cited by this paper
• DNA methylation protects hematopoietic stem cell multipotency from myeloerythroid restriction

  2009cited by this paper
• Decitabine Effect on Tumor Global DNA Methylation and Other Parameters in a Phase I Trial in Refractory Solid Tumors and Lymphomas

  2009cited by this paper
• DNA methyltransferase 1 is essential for and uniquely regulates hematopoietic stem and progenitor cells.

  2009cited by this paper
• Mechanisms of resistance to 5-aza-2'-deoxycytidine in human cancer cell lines.

  2009cited by this paper
• DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation

  2009cited by this paper
• Polycomb group proteins: navigators of lineage pathways led astray in cancer

  2009cited by this paper
• Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia.

  2008cited by this paper
• A Phase I and Pharmacokinetic Study of the Oral Histone Deacetylase Inhibitor, MS-275, in Patients with Refractory Solid Tumors and Lymphomas

  2008cited by this paper
• Cytosine methylation profiling of cancer cell lines

  2008cited by this paper
• Interferon-α is able to maintain complete molecular remission induced by imatinib after its discontinuation

  2008cited by this paper
• MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo

  2008cited by this paper
• Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma

  2008cited by this paper
• Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma.

  2008cited by this paper
• Frequent switching of Polycomb repressive marks and DNA hypermethylation in the PC3 prostate cancer cell line

  2008cited by this paper
• Acetylation is indispensable for p53 activation.

  2008cited by this paper
• Phase II Trial of Oral Panobinostat (LBH589) in Patients with Refractory Cutaneous T-Cell Lymphoma (CTCL).

  2008cited by this paper
• Gene expression analysis of peripheral T cell lymphoma, unspecified, reveals distinct profiles and new potential therapeutic targets.

  2007cited by this paper
• UTX and JMJD3 are histone H3K27 demethylases involved in HOX gene regulation and development

  2007cited by this paper
• A histone H3 lysine 27 demethylase regulates animal posterior development

  2007cited by this paper
• Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma.

  2007cited by this paper
• PVRL2 is translocated to the TRA@ locus in t(14;19)(q11;q13)‐positive peripheral T‐cell lymphomas

  2007cited by this paper
• A comprehensive genetic and histopathologic analysis identifies two subgroups of B-cell malignancies carrying a t(14;19)(q32;q13) or variant BCL3-translocation

  2007cited by this paper
• Further delineation of chromosomal consensus regions in primary mediastinal B-cell lymphomas: an analysis of 37 tumor samples using high-resolution genomic profiling (array-CGH)

  2007cited by this paper
• Gene expression analysis of angioimmunoblastic lymphoma indicates derivation from T follicular helper cells and vascular endothelial growth factor deregulation.

  2007cited by this paper
• Demethylation of H3K27 Regulates Polycomb Recruitment and H2A Ubiquitination

  2007cited by this paper
• Treatment of Relapsed or Refractory Lymphoma with the Oral Isotype-Selective Histone Deacetylase Inhibitor MGCD0103: Interim Results from a Phase II Study.

  2007cited by this paper
• Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells.

  2007cited by this paper
• Epigenetic stem cell signature in cancer

  2007cited by this paper

• High-throughput epigenetic profiling immunoassays for accelerated disease research and clinical development

  2025cites this paper
• The EBV-Positive Tumor Methylome Is Distinct from EBV-Negative in Diffuse Large B-Cell Lymphoma

  2025cites this paper
• The inhibitory and transcriptional effects of the epigenetic repurposed drugs hydralazine and valproate in lymphoma cells.

  2024cites this paper
• Epigenetic profiles of elevated cell free circulating H3.1 nucleosomes as potential biomarkers for non-Hodgkin lymphoma

  2023cites this paper
• Premature senescence and cardiovascular disease following cancer treatments: mechanistic insights

  2023cites this paper
• Epigenetic targets in B- and T-cell lymphomas: latest developments

  2023cites this paper
• Evaluation of the Synergistic Potential of Simultaneous Pan- or Isoform-Specific BET and SYK Inhibition in B-Cell Lymphoma: An In Vitro Approach

  2022cites this paper
• The Synergistic Anti-Tumor Activity of EZH2 Inhibitor SHR2554 and HDAC Inhibitor Chidamide through ORC1 Reduction of DNA Replication Process in Diffuse Large B Cell Lymphoma

  2021cites this paper
• Alterations of 5-hydroxymethylation in circulating cell-free DNA reflect molecular distinctions of subtypes of non-Hodgkin lymphoma

  2021cites this paper
• Targeting Histone Deacetylases to Modulate Graft-Versus-Host Disease and Graft-Versus-Leukemia

  2020cites this paper
• Silencing of long noncoding RNA HOXA11-AS inhibits the Wnt signaling pathway via the upregulation of HOXA11 and thereby inhibits the proliferation, invasion, and self-renewal of hepatocellular carcinoma stem cells

  2019cites this paper
• Recent Advances in the Targeting of Epigenetic Regulators in B-Cell Non-Hodgkin Lymphoma

  2019cites this paper
• Genetic convergence of rare lymphomas

  2018cites this paper
• Are lymphomas result of aberrant epigenentic regulation of immune system? molecular insights and therapeutic prospects

  2018influential citation
• Schwerpunktthema: Personalisierte Medizin in der Onkologie

  2017cites this paper
• Deregulated expression of HDAC9 in B cells promotes development of lymphoproliferative disease and lymphoma in mice

  2016cites this paper
• The role of the polycomb repressive complex pathway in T and NK cell lymphoma: biological and prognostic implications

  2016cites this paper
• New drugs for the treatment of non-Hodgkin lymphomas.

  2015cites this paper
• Histone deacetylase inhibitors and epigenetic regulation in lymphoid malignancies

  2015cites this paper
• Las alteraciones epigenéticas en la progresión del cáncer

  2014cites this paper
• The changing landscape of peripheral T-cell lymphoma in the era of novel therapies.

  2014cites this paper
• Macroglobulinemia de Waldenström: una visión general

  2014cites this paper